Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
|Articles|December 20, 2021
Pharmacy Clinical Pearl of the Day: Mononucleosis
Author(s)Saro Arakelians, PharmD
Mononucleosis isn't as contagious as some infections, such as the common cold.
Advertisement
Clinical Pearl of the Day: Mononucleosis
Infectious mononucleosis (mono) is often called the kissing disease.
Insight:
- The virus that causes mono (Epstein-Barr virus) is spread through saliva.
- Mononucleosis can be passed through kissing, but exposure can also occur by sharing a glass or food utensils with someone who has mono. However, mononucleosis isn't as contagious as some infections, such as the common cold.
- Symptoms may include fatigue, sore throat, fever, swollen lymph, swollen tonsils, headache, skin rash, and swollen spleen.
- Causes: The most common cause of mononucleosis is the Epstein-Barr virus, but other viruses also can cause similar symptoms.
- Diagnosis may include antibody testing as well as white blood cell count.
- Preventive tools may include gargling with salt water, OTC pain relievers, and drinking plenty of fruits juices and water.
- Treatment may include antibiotics, such as amoxicillin and penicillin.
Sources:
Advertisement
Related to this article
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5